OBJECTIVE: The goal of this study was to characterize types, frequency, combinations, and relative onset of symptoms among ovarian cancer cases and controls. METHODS: Participants were from an ongoing, population-based, case-control study of primary epithelial ovarian cancer in a 48-country region of North Carolina. Incident cases (N = 267), aged 20-74, were identified by area hospitals on a rapid case ascertainment basis between April 1999 and March 2001. Population-based controls, with at least one intact ovary, frequency matched on age and race, were identified using random-digit dialing (N = 287) and Health Care Financing Administration (HCFA) phone lists (N = 30). Trained nurse-interviewers, using a standardized questionnaire, asked participants about specific symptoms experienced for at least 2 weeks in the year prior to diagnosis (cases)/interview (controls). RESULTS: More than 90% of cases reported at least one symptom and symptoms were most often the reason for the doctor visit leading to diagnosis (74%), followed by routine examination (12%). Among invasive cases, symptoms with onsets longer before diagnosis (median 5-7 months) included gas/nausea/indigestion; urinary frequency/urgency; bowel irregularity; abnormal menstrual/vaginal bleeding or discharge; pain during intercourse; and ongoing fatigue. Symptoms with onsets closer to diagnosis (median of 2-4 months) included distended/hard abdomen; bloating/feeling of fullness; unexplained weight gain/loss; pelvic/abdominal discomfort; chest pain/respiratory difficulties; and "other" symptoms. Controls reported fewer symptoms than cases (median 1 vs 5 or 6). Control symptoms were of longer duration and much less likely to occur in combination. CONCLUSION: Earlier diagnosis of ovarian cancer may be possible if women and physicians recognize the importance of combinations of seemingly unrelated symptoms, especially those identified as occurring longer before diagnosis.
OBJECTIVE: The goal of this study was to characterize types, frequency, combinations, and relative onset of symptoms among ovarian cancer cases and controls. METHODS:Participants were from an ongoing, population-based, case-control study of primary epithelial ovarian cancer in a 48-country region of North Carolina. Incident cases (N = 267), aged 20-74, were identified by area hospitals on a rapid case ascertainment basis between April 1999 and March 2001. Population-based controls, with at least one intact ovary, frequency matched on age and race, were identified using random-digit dialing (N = 287) and Health Care Financing Administration (HCFA) phone lists (N = 30). Trained nurse-interviewers, using a standardized questionnaire, asked participants about specific symptoms experienced for at least 2 weeks in the year prior to diagnosis (cases)/interview (controls). RESULTS: More than 90% of cases reported at least one symptom and symptoms were most often the reason for the doctor visit leading to diagnosis (74%), followed by routine examination (12%). Among invasive cases, symptoms with onsets longer before diagnosis (median 5-7 months) included gas/nausea/indigestion; urinary frequency/urgency; bowel irregularity; abnormal menstrual/vaginal bleeding or discharge; pain during intercourse; and ongoing fatigue. Symptoms with onsets closer to diagnosis (median of 2-4 months) included distended/hard abdomen; bloating/feeling of fullness; unexplained weight gain/loss; pelvic/abdominal discomfort; chest pain/respiratory difficulties; and "other" symptoms. Controls reported fewer symptoms than cases (median 1 vs 5 or 6). Control symptoms were of longer duration and much less likely to occur in combination. CONCLUSION: Earlier diagnosis of ovarian cancer may be possible if women and physicians recognize the importance of combinations of seemingly unrelated symptoms, especially those identified as occurring longer before diagnosis.
Authors: Viola Andresen; Jutta Keller; Christian Pehl; Michael Schemann; Jan Preiss; Peter Layer Journal: Dtsch Arztebl Int Date: 2011-11-04 Impact factor: 5.594
Authors: Barbara A Goff; Kimberly A Lowe; Jeannette C Kane; Marissa D Robertson; Marcia A Gaul; M Robyn Andersen Journal: Gynecol Oncol Date: 2011-11-06 Impact factor: 5.482
Authors: Galina Lurie; Lynne R Wilkens; Pamela J Thompson; Rayna K Matsuno; Michael E Carney; Marc T Goodman Journal: Gynecol Oncol Date: 2010-06-29 Impact factor: 5.482
Authors: Mary Anne Rossing; Kristine G Wicklund; Kara L Cushing-Haugen; Noel S Weiss Journal: J Natl Cancer Inst Date: 2010-01-28 Impact factor: 13.506
Authors: Megan A Mullins; Lauren C Peres; Anthony J Alberg; Elisa V Bandera; Jill S Barnholtz-Sloan; Melissa L Bondy; Ellen Funkhouser; Patricia G Moorman; Edward S Peters; Paul D Terry; Ann G Schwartz; Andrew B Lawson; Joellen M Schildkraut; Michele L Cote Journal: Cancer Date: 2019-08-15 Impact factor: 6.860
Authors: Chioma O Erondu; Anthony J Alberg; Elisa V Bandera; Jill Barnholtz-Sloan; Melissa Bondy; Michele L Cote; Ellen Funkhouser; Edward Peters; Ann G Schwartz; Paul D Terry; Kristin Wallace; Lucy Akushevich; Frances Wang; Sydnee Crankshaw; Andrew Berchuck; Joellen M Schildkraut; Patricia G Moorman Journal: J Womens Health (Larchmt) Date: 2016-02-17 Impact factor: 2.681